Recombinant, highly effective, adjuvant subunit totivaccine. Shingrix is the first dead vaccine against Herpes Zoster that triggers a targeted immune response through a specially developed adjuvant. This induces a strong and sustained immunity in older people. The vaccine Shingrix contains the glycoprotein E as antigen and is designed to induce an antigen-specific cellular and humoral immune response in persons already immune to Varicella zoster virus.
Shingrix
DefinitionThis section has been translated automatically.
IndicationThis section has been translated automatically.
Prevention of zoster and post-zoster neuralgia (PZN) in adults aged 50 years and older
Dosage and method of useThis section has been translated automatically.
Shingrix is administered intramuscularly twice at intervals of 2-6 months
Undesirable effectsThis section has been translated automatically.
pain at the injection site, myalgia (muscle pain), fatigue and headaches
PreparationsThis section has been translated automatically.
Shingrix was investigated in two placebo-controlled studies involving a total of 38,000 adults. The main indicator of efficacy in both studies was the number of people with zoster in each group. The number of people who developed post-zosteric neuralgia after vaccination was also determined.
In the first study (patients age 50 years and > 50 years), 7,695 people received Shingrix and 7,710 received a placebo. In the follow-up period of 3 years on average, 6 patients in the Shingrix group developed zoster (210 adults in the placebo group). After almost 4 years, none of the adults in the Shingrix group had developed post-zosteric neuralgia (18 patients in the placebo group). In this study, Shingrix prevented the occurrence of zoster in 97% of cases and post-zosteric neuralgia in 100% of cases.
In a second study (patients age 70 years and > 70 years) 8,250 people received Shingrix and 8,346 PLazebo. In the follow-up period of 4 years on average, 25 adults who received Shingrix received zoster infection (284 patients in the placebo group). Over a period of 4 years, 4 patients in the Shingrix group developed post-zosteric neuralgia (36 patients in the placebo group).
Note(s)This section has been translated automatically.
Besides Shingrix, Zostavax (MSD Sharp & Dohme) is a (live) vaccine against herpes zoster.
LiteratureThis section has been translated automatically.
- Bharucha T et al (2017) A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. Hum Vaccine Immunother 13:1789-1797.
- James SF et al (2018) Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine. Ann Pharmacother 52:673-680.
- Symoniak MR et al (2018) Herpes zoster subunit vaccine for the prevention of herpes zoster. At J Health Syst Pharm 75:861-869.